Rigel Pharmaceuticals
RIGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$787.26M
Close$
$-32.26
178.3% downside
Current Fair Value
178.3% downsideOvervalued by 178.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $787.26 Million |
|---|---|
| Enterprise Value | $808.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.4 |
| Beta | 1.13 |
| Outstanding Shares | 18,412,000 |
Return
| Return on Equity | 91.08% |
|---|---|
| Return on Assets | 72.18% |
| Return on Invested Capital | 29.72% |
Valuation & Multiples
| P/E Ratio | 2.12 |
|---|---|
| PEG | -8.69 |
| Price to Sales | 2.57 |
| Price to Book Ratio | 1.96 |
| Enterprise Value to Revenue | 2.7 |
| Enterprise Value to EBIT | 6.55 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$0.74
Average shareholder expectationRevenue Estimate
$62.40 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$56.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 74.32% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.48%▼ 88.49% |
|---|---|
| Total Invested | $3.48M▼ 99.20% |
| Investors Holding | 3▼ 152.00% |
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez